Martin Shkreli in 2022 was banned from the pharmaceutical industry and ordered to disgorge profits earned from raising the price of the drug Daraprim.
The Supreme Court on Monday rejected a bid by notorious ‘pharma bro’ Martin Shkreli to hear his appeal of a $64 million financial penalty on the fraudster for blocking competition to a life-saving drug whose price he had raised by more than $700 per pill.
Shkreli’s request that the Supreme Court take his appeal of federal court decision was his last chance to overturn the penalty related to the drug Daraprim.
The Supreme Court in rejecting that request did not explain its reason for doing so. There were no noted dissents by any justice to the decision.
CNBC has requested comment from Shkreli’s lawyer and the Federal Trade Commission, whose lawsuit against Shkreli led to the penalty.
Shkreli gained national infamy in 2015 when his drug company hiked the price of Daraprim by more than 4,000%.
